drugset / Trial / NCT05946226
A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors
NaSequentialOpen-labelTreatment
Summary
This is an open-label, multi-center, dose-escalation clinical study to evaluate the safety, feasibility, and preliminary efficacy of IMC002 in patients with CLDN18.2 positive digestive system tumors including but not limited to advanced gastric cancer, esophagogastric junction adenocarcinoma, and advanced pancreatic cancer.
Timeline
- Start
- 2023-09-07
- Primary completion
- 2025-12-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMC-002 | Unknown | 1e+08 cells | — |
| Subject | IMC-002 | Unknown | 2.5e+08 cells | — |
| Subject | IMC-002 | Unknown | 5e+08 cells | — |